DRW Securities LLC Decreases Stake in Novartis AG (NYSE:NVS)

DRW Securities LLC decreased its holdings in Novartis AG (NYSE:NVS) by 15.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 39,405 shares of the company’s stock after selling 6,928 shares during the quarter. DRW Securities LLC’s holdings in Novartis were worth $4,190,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Novartis by 23.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock worth $788,626,000 after acquiring an additional 1,389,610 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Novartis by 191.1% during the second quarter. Bank of New York Mellon Corp now owns 1,904,664 shares of the company’s stock worth $202,771,000 after purchasing an additional 1,250,318 shares in the last quarter. Magnetar Financial LLC grew its holdings in Novartis by 53.7% in the first quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company’s stock valued at $184,372,000 after purchasing an additional 666,104 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Novartis in the second quarter valued at $64,610,000. Finally, Mondrian Investment Partners LTD raised its stake in shares of Novartis by 40.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company’s stock worth $199,819,000 after buying an additional 590,830 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Down 0.0 %

Shares of NYSE:NVS opened at $115.94 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47. The firm has a market cap of $236.98 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 1.75 and a beta of 0.57. The stock’s 50-day moving average price is $114.22 and its two-hundred day moving average price is $105.48. Novartis AG has a 12-month low of $92.19 and a 12-month high of $120.92.

Novartis (NYSE:NVS) last released its earnings results on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. The firm had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same period in the previous year, the firm earned $1.83 earnings per share. On average, research analysts forecast that Novartis AG will post 7.5 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on NVS shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a research report on Friday, July 19th. Barclays upgraded Novartis to a “strong sell” rating in a research report on Monday, June 24th. Bank of America cut Novartis from a “buy” rating to a “neutral” rating and lowered their target price for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. The Goldman Sachs Group reissued a “neutral” rating and issued a $121.00 price target (up from $119.00) on shares of Novartis in a report on Thursday, September 5th. Finally, Jefferies Financial Group cut Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $120.70.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.